Financings Of The Fortnight: Alexza's Loxapine Program Finally Comes Together
This article was originally published in The Pink Sheet Daily
Executive Summary
Alnara raises a $35 million Series B to complete development of a non-porcine pancreatic enzyme replacement therapy, while oncology biotech Syndax topped off a 2007 Series A with an additional $9 million.
You may also be interested in...
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.
Otsuka Busulfex's Overall Survival Claim Does Not Survive CDER Advertising Scrutiny
Statistical analyses based on pivotal trial data and used to promote a drug must prove what they purport to prove, FDA's Office of Prescription Drug Promotion says in an NOV letter to Otsuka over a website for the leukemia drug Busulfex (busulfan).